Malaria Vaccine Development Advances

Posted: November 6th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , | Comments Off on Malaria Vaccine Development Advances

GenVec inked a $3.5 million agreement with the Naval Medical Research Center o support malaria vaccine development.

The Gaithersburg, MD-based company will produce supplies of its vaccine for use in clinical trials.  The company retains the right to commercialize the product.  The NMRC will assess the safety and efficacy of the vaccines in a clinical challenge model it developed with Walter Reed Army Institute of Research malaria vaccine programs.  Those programs are now unified as the U.S. Military Vaccine Program.

NMRC and WRAIR tested out GenVec’s candidate in April 2010 in a Phase I trial.  The data from the trial indicated the vaccine is safe, “causing minimal local or systemic reactions and no serious vaccine-related adverse reactions,” according to GenVec’s statement.  And four out of 15 volunteers inoculated with the vaccine showed a complete absence of parasites in the blood.

New Vaccine Shows Good Results in Testing

Posted: November 1st, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , | Comments Off on New Vaccine Shows Good Results in Testing

Pfizer posted positive results in a late-stage study of its Prevnar 13 vaccine. The study of the shot, known as Prevnar in the U.S. and Prevenar in other countries and used to prevent infection by streptococcus pneumonia, showed that the immune response to the vaccine in the 18- to 49-year-old age group was noninferior when compared to the response in the 60- to 64-year-old age group.

The objective was met for all 13 serotypes in Prevnar 13, and the data support a recent regulatory submission to expand the indication of Prevnar 13 in the EU to include adults between 18 and 49 years old. Pfizer will also use study results to support similar planned submissions in other countries.

“Prevenar 13 is the first and only pneumococcal conjugate vaccine for adults, and we continue to study the vaccine in new populations with the aim of broadening its availability,” William Gruber, senior vice president of Vaccine Clinical Research and Development at Pfizer, said in a release.

The positive results come less than a month after the World Health Organization granted prequalification for the vaccine in adults over the age of 50, a decision that expanded the global market for the company’s lead vaccine.

Prevnar 13 is already approved in 110 countries for infants and young children. But only about 70 countries, including the U.S., approve it for adults over 50.